Dyax is a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients with rare diseases. Founded in 1995 on our proprietary phage display technology platform, we have leveraged this capability to develop new treatments for hereditary angioedema (HAE), a rare, potentially life-threatening genetic disease. We currently market KALBITOR® (ecallantide) for the treatment of acute attacks of HAE and are advancing DX-2930, an investigational drug candidate for the prevention of HAE attacks. We are also applying our understanding of human monoclonal antibody development to expand our product pipeline to include disorders of thrombosis, immune dysregulation, and vascular disease.
In addition to our internally developed products, we have broadly licensed our phage display technology and have a portfolio of product candidates being developed by our licensees. Our Licensing and Funded Research Portfolio (LFRP) includes one approved product for which we receive royalties and several product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties.
At Dyax, our goal is to become a global leader in the biopharmaceutical industry and we are driven by one unifying purpose: improving the lives of patients.
(Ticker: DYAX) See investor information.